These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

301 related items for PubMed ID: 23529616

  • 1. Infection with Francisella tularensis LVS clpB leads to an altered yet protective immune response.
    Barrigan LM, Tuladhar S, Brunton JC, Woolard MD, Chen CJ, Saini D, Frothingham R, Sempowski GD, Kawula TH, Frelinger JA.
    Infect Immun; 2013 Jun; 81(6):2028-42. PubMed ID: 23529616
    [Abstract] [Full Text] [Related]

  • 2. Interleukin-17 protects against the Francisella tularensis live vaccine strain but not against a virulent F. tularensis type A strain.
    Skyberg JA, Rollins MF, Samuel JW, Sutherland MD, Belisle JT, Pascual DW.
    Infect Immun; 2013 Sep; 81(9):3099-105. PubMed ID: 23774604
    [Abstract] [Full Text] [Related]

  • 3. An In Vitro Co-culture Mouse Model Demonstrates Efficient Vaccine-Mediated Control of Francisella tularensis SCHU S4 and Identifies Nitric Oxide as a Predictor of Efficacy.
    Golovliov I, Lindgren H, Eneslätt K, Conlan W, Mosnier A, Henry T, Sjöstedt A.
    Front Cell Infect Microbiol; 2016 Sep; 6():152. PubMed ID: 27933275
    [Abstract] [Full Text] [Related]

  • 4. Live Attenuated Tularemia Vaccines for Protection Against Respiratory Challenge With Virulent F. tularensis subsp. tularensis.
    Jia Q, Horwitz MA.
    Front Cell Infect Microbiol; 2018 Sep; 8():154. PubMed ID: 29868510
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.
    Jia Q, Lee BY, Bowen R, Dillon BJ, Som SM, Horwitz MA.
    Infect Immun; 2010 Oct; 78(10):4341-55. PubMed ID: 20643859
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Francisella tularensis Live Vaccine Strain training of murine alveolar and bone marrow-derived macrophages.
    Khan H, Bhargava V, Elkins KL.
    Microbiol Spectr; 2024 Aug 06; 12(8):e0002824. PubMed ID: 38940590
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Construction and characterization of an attenuated purine auxotroph in a Francisella tularensis live vaccine strain.
    Pechous R, Celli J, Penoske R, Hayes SF, Frank DW, Zahrt TC.
    Infect Immun; 2006 Aug 06; 74(8):4452-61. PubMed ID: 16861631
    [Abstract] [Full Text] [Related]

  • 13. Further Characterization of the Capsule-Like Complex (CLC) Produced by Francisella tularensis Subspecies tularensis: Protective Efficacy and Similarity to Outer Membrane Vesicles.
    Champion AE, Bandara AB, Mohapatra N, Fulton KM, Twine SM, Inzana TJ.
    Front Cell Infect Microbiol; 2018 Aug 06; 8():182. PubMed ID: 29963499
    [Abstract] [Full Text] [Related]

  • 14. Francisella tularensis live vaccine strain folate metabolism and pseudouridine synthase gene mutants modulate macrophage caspase-1 activation.
    Ulland TK, Janowski AM, Buchan BW, Faron M, Cassel SL, Jones BD, Sutterwala FS.
    Infect Immun; 2013 Jan 06; 81(1):201-8. PubMed ID: 23115038
    [Abstract] [Full Text] [Related]

  • 15. Attenuation and protective efficacy of an O-antigen-deficient mutant of Francisella tularensis LVS.
    Li J, Ryder C, Mandal M, Ahmed F, Azadi P, Snyder DS, Pechous RD, Zahrt T, Inzana TJ.
    Microbiology (Reading); 2007 Sep 06; 153(Pt 9):3141-3153. PubMed ID: 17768257
    [Abstract] [Full Text] [Related]

  • 16. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis.
    KuoLee R, Harris G, Conlan JW, Chen W.
    Vaccine; 2007 May 10; 25(19):3781-91. PubMed ID: 17346863
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection.
    Kurtz SL, Foreman O, Bosio CM, Anver MR, Elkins KL.
    Infect Immun; 2013 Feb 10; 81(2):585-97. PubMed ID: 23230288
    [Abstract] [Full Text] [Related]

  • 20. Kdo hydrolase is required for Francisella tularensis virulence and evasion of TLR2-mediated innate immunity.
    Okan NA, Chalabaev S, Kim TH, Fink A, Ross RA, Kasper DL.
    mBio; 2013 Feb 12; 4(1):e00638-12. PubMed ID: 23404403
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.